Table 3 Gender-stratified TEs.
From: Real-world assessment of thromboembolic risk associated with tamoxifen
PT | Famale | Male | ||
|---|---|---|---|---|
n | ROR (95% Cl) | n | ROR (95% Cl) | |
Arterial thromboembolism (ATE) | ||||
Ischaemic stroke | 17 | 6.07 (3.77–9.77) | 3 | 13.61 (4.38–42.34) |
Peripheral artery thrombosis | 7 | 30.71 (14.57–64.71) | ||
Retinal artery occlusion | 6 | 16.09 (7.21–35.9) | ||
Blindness transient | 5 | 3.78 (1.57–9.08) | ||
Coronary artery embolism | 3 | 851.62(269.8-2688.10) | ||
Venous thromboembolism (VTE) | ||||
Pulmonary embolism | 96 | 5.09 (4.16–6.22) | 15 | 15.98 (9.57–26.69) |
Deep vein thrombosis | 60 | 4.65 (3.61–6.00) | 8 | 12.05 (6.00–24.22) |
Cerebral venous thrombosis | 19 | 48.48 (30.78–76.34) | ||
Pulmonary thrombosis | 9 | 4.15 (2.16–7.98) | ||
Superior sagittal sinus thrombosis | 6 | 31.47 (14.07–70.39) | ||
Thrombophlebitis | 6 | 8.33 (3.74–18.56) | ||
Budd-Chiari syndrome | 5 | 105.09 (42.98–256.96) | ||
Portal vein thrombosis | 5 | 11.45 (4.76–27.57) | 3 | 70.86 (22.76–220.63) |
Retinal vein occlusion | 5 | 10.44 (4.34–25.14) | ||
Venous thrombosis limb | 5 | 11.50 (4.78–27.69) | ||
Embolism venous | 4 | 9.12 (3.42–24.35) | ||
Transverse sinus thrombosis | 4 | 26.08 (9.74–69.83) | ||
Superficial vein thrombosis | 4 | 46.70 (17.37–125.55) | ||
Jugular vein thrombosis | 3 | 7.79 (2.51–24.21) | ||
Unspecified thromboembolism | ||||
Thrombosis | 51 | 3.37 (2.56–4.43) | 8 | 9.31 (4.63–18.71) |
Monoplegia | 6 | 6.86 (3.08–15.30) | ||
Antiphospholipid syndrome | 3 | 8.84 (2.85–27.48) | ||
